Phenotype of asthma related with high serum periostin levels

Matsusaka, Masako; Kabata, Hiroki; Fukunaga, Koichi; Suzuki, Yusuke; Masaki, Katsunori; Mochimaru, Takao; Sakamaki, Fumio; Oyamada, Yoshitaka; Inoue, Takashi; Oguma, Tsuyoshi; Sayama, Koichi; Koh, Hidefumi; Nakamura, Morio; Umeda, Akira; Ono, Junya; Ohta, Shoichiro; Izuhara, Kenji; Asano, Koichiro; Betsuyaku, Tomoko

doi:10.1016/j.alit.2014.07.003

Cited by 111 publications

(91 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These data are also supported by the results of another study performed on asthmatic patients type "Th2-high", in which IL-13 has been associated with an increased serpinB2, Clca1 and POSTN gene expression in airway epithelial brushings [20,21]. An increased eosinophilic inflammation in bronchial mucosa has been also noticed, in association with respiratory epithelium basement membrane thickening, and a fast decline of lung function despite the aggressive corticosteroid therapy.…”

Section: Periostin and Bronchial Asthmasupporting

confidence: 75%

Periostin in bronchial asthma – a brief update

Grigoraș¹,

Lozneanu²,

Grigoraş³

et al. 2017

Arch Clin Cases

View full text Add to dashboard Cite

Periostin is an extracellular matrix protein which intervenes in the regulation of angiogenesis, and in tumoral cells proliferation and invasion. Recent studies, mainly experimental models, have demonstrated the intervention of this molecule in asthmatic disease, by eosinophils recruitment, bronchial wall remodeling, and by stimulation of inflammatory cytokines production. Currently, periostin is considered a marker of type 2 inflammation in asthma, being secreted by respiratory epithelial cells triggered by IL-13 and IL-4. Concomitantly, periostin accumulated at the bronchial epithelial-connective tissue interface is involved in fibrogenesis and mucus secretion, in correlation with the intensity of bronchial mucosa eosinophilic inflammatory infiltrate. However, the intimate molecular mechanisms of periostin involvement in the pathogenic pathway of asthmatic diseases is far away from elucidation, further research being necessary to certify its value as a biomarker useful in diagnosis and in establishment of therapeutic schemes in bronchial asthma.

show abstract

Section: Periostin and Bronchial Asthmasupporting

confidence: 75%

Periostin in bronchial asthma – a brief update

Grigoraș¹,

Lozneanu²,

Grigoraş³

et al. 2017

Arch Clin Cases

View full text Add to dashboard Cite

show abstract

“…Periostin in BLF was detected as previously described with a slight modification, using the biotin-stereptavidin system to increase the sensitivity. 2,9,10 The BLF from seven asthma patients showed no detectable periostin (data not shown). Although periostin was detectable in the BLF of the remaining three asthma patients, the periostin levels were less than 200 pg/mL.…”

Section: Dear Editormentioning

confidence: 85%

Periostin in the bronchial lavage fluid of asthma patients

Nakamura

Nagashima

Ono³

et al. 2015

Allergology International

Self Cite

View full text Add to dashboard Cite

“…According to some authors, this protein is a safe and stable biomarker of chronic inflammation [17] and of the T H 2 mechanism underlying severe asthma in adults [10]. A link has been established between periostin and bronchial obstruction, elevated levels of fractional exhaled nitric oxide (FeNO), and eosinophil count in adults [18][19][20]. One of the effects of periostin is to attract inflammatory cells-neutrophils or eosinophils-to the airway.…”

Section: Introductionmentioning

confidence: 99%

Role of Periostin in Uncontrolled Asthma in Children (DADO study)

Mena

Abejón

Vidigal

et al. 2017

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

Background: Asthma is the most common chronic disease in children. Cases of severe asthma (SA) are underdiagnosed. Periostin is a biomarker for SA in adults, but its role in children is poorly understood. Objectives: The aims of the study were to estimate the percentage of cases of uncontrolled severe asthma (UcSA) in children with poorly controlled asthma and to evaluate the role of periostin as a biomarker. Materials and Methods: We performed an observational study in children aged 5 to 14 years with poorly controlled asthma. Demographic and clinical data were collected in addition to the results of the lung function test, the fraction of exhaled nitric oxide, the skin prick test, total IgE, specific IgE, blood eosinophil count, serum periostin, treatment, asthma control, and quality of life. Variables were compared between the group with UcSA and the other children. Results: Fifty children with poorly controlled asthma (72% male) were included. Nineteen children (38%) had UcSA. Most children had limitations in their activities of daily living and had visited the emergency department. In addition, 38% were hospitalized. Quality of life was poor. Only 42% of the children received appropriate treatment. The UcSA group was more likely to have a total IgE >500 kU A /mL (52.6% vs 19%, P=.02) and less likely to have serum periostin >1000 ng/mL (31.2% vs 63%, P=.04). Conclusions: In our setting, 38% of children with poorly controlled asthma have UcSA, which is associated with higher levels of total serum IgE and lower levels of serum periostin.

show abstract

Phenotype of asthma related with high serum periostin levels

Abstract: Elevated periostin concentrations in serum were correlated with a specific phenotype of eosinophilic asthma, late-onset and often complicated by obstructive pulmonary dysfunction and nasal disorders.

Cited by 111 publications

References 25 publications

Periostin in bronchial asthma – a brief update

Periostin in bronchial asthma – a brief update

Periostin in the bronchial lavage fluid of asthma patients

Role of Periostin in Uncontrolled Asthma in Children (DADO study)

Contact Info

Product

Resources

About